What result does the doctor and patient expect when treating psoriasis

Cite item

Full Text

Review of L.P. Kotrehova speech

##article.viewOnOriginalSite##

Клинические рекомендации «Псориаз». Одобрено научно-практическим советом Минздрава России. https://cr.rosminzdrav.rU/#1/schema/866
Mirowietz et al. Arch Dermatol Res 2011; 303: 1-10.
Girolomoni G et al. Br J Dermatol 2012; 167: 717-24.
Lynde CW et al. J Am Acad Dermatol 2014; 71: 141-50.
Lee E et al. J Drugs Dermatol 2015; 14: 1133-6;
Ventura A et al. Drug Design Devel Therapy 2017; 11: 2525-35.
Schett G et al. Nat Rev Rheumatol 2017; 13: 731-41.
Langley R et al. NEJM 2014; 371: 326.
Blauvelt A et al. J Am Acad Dermatol 2017; 76; 60-69.e69.
Bagel J et al. 2018. EADV 2018.
Zarif K. Jabbar-Lopez et al. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. J Invest Dermatol. 2017; 137 (8): 1646-54.
Deodhar AA, Gladman DD, McInnes IB et al. Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 patient-treatment years exposure. Arthritis Rheumatol. 2018; 70 (Suppl. 10). https://acrabstracts.org/ab-stract/post-marketing-safety-of-secukinumab-in-adult-patients-with-psoriasis-psoriatic-arthritis-and-an-kylosing-spondylitis-cumulative-analysis-across-96000-patient-treatment-years-exposure
Инструкция по медицинскому применению препарата Козэнтикс РУ ЛП-003715.